dementia: from prevention to cure
DESCRIPTION
TRANSCRIPT
Dementia: from prevention to cure
Christopher PattersonMcMaster University,
Hamilton, OntarioCanada
Objectives
• Define dementia
• Describe epidemiology of dementia in India
• Distinguish the common types of dementia
• Describe “standard” investigation of suspected dementia
• Introduce principles of management
• Touch on future trends
Dementia: A syndrome
• An acquired disorder• Diffuse cognitive deficits: memory (usually)
aphasia, apraxia, agnosia, executive dysfunction
• Deficits sufficient to interfere with daily function
• Not occurring solely in delirium or depression
CMAJ 1999;160 (12 suppl)
Prevalence of dementia in India
• Low estimate 1.9% over age 65 (Ferri C et al Lancet 2005; 366: 2112)
• Higher estimate 2.7% over age 65 (Kalaria R et al Lancet Neurology 2008; 7:812)
Highest estimate of prevalence: Kerala India
• Door to door survey• Screen with MMSE• Full assessment if < 23
Age 65-69 70-74 75-79 80-84 85-89 90+
% 0.6 2.0 5.2 7.1 11.8 13.3
Shaji S et al Br J Psychiatr 2005; 186: 136
Global burden of Dementia10/66 Dementia Research Group
Risk Factors for Alzheimer’s disease• Age• Family history• Lifestyle Physical exercise Mental exercise Diet Tobacco Head injury
• Hypertension • Elevated serum cholesterol• Elevated serum homocysteine
Risk Factors for Alzheimer’s disease
Risk Factors for Alzheimer’s disease
Can we predict who will develop dementia?
Knowing the following risk factors in middle age a calculation of future likelihood of dementia:
• Age• Level of permits education• Systolic BP• BMI• Total serum cholesterol• Degree of physical activity
Patterson C et al CMAJ 2008; 178:548
Calculating future risk Patterson C et al CMAJ 2008; 178:548
Types of Dementia
• Alzheimer’s
• Mixed
• Lewy-body
• Frontotemporal
• Vascular• Other neurodegenerations (e.g.Huntingdon’s)
• Infections (e.g. HIV,Jakob-Creutzfeld)
Types of Dementia
• Alzheimer’s
• Mixed ► 80% of all dementias
• Lewy-body
• Frontotemporal
• Vascular• Other neurodegenerations (e.g.Huntingdon’s)
• Infections (e.g. HIV,Jakob-Creutzfeld)
VaDVaD ADADMixed
Interactions Between Vascular Dementia and Alzheimer’s
Disease
80% of all Dementias80% of all Dementias
The Nun Study
• Longitudinal study of the Teaching Sisters of Notre Dame (USA)
• 678 enrolled since 1991 aged 75-102• Written autobiographies within 2 years of entry• Annual cognitive testing• Brain autopsies• 400 deceased by 2003
Snowdon DA Ann Intern Med 2003;139: 450
The Nun Study
• Early linguistic ability predicts later dementia
• Severity of Alzheimer changes (amyloid plaques, neurofibrillary tangles) did not always correlate with cognitive changes
• Presence of stroke (especially small WM) increased clinical dementia (RR=20)
The Nun Study: pathology of those with dementia
Alzheimers alone 43%
Mixed (AD + strokes) 34%
Other types of pathology 20%
Vascular alone 2.5%
Pure vascular dementia is relatively rare
• Several clinicopathological studies
• Vascular dementias suspected commonly in life
• At autopsy, vascular pathology alone rarely explained clinical features
• Mixed pathology common
• BUT may be more common in Asian counties
Symptomatic Domains of AD Over Time
Mood
CognitiveFunction
FunctionalAutonomy
BehaviourProblems
Adapted from Gauthier et al. Clinical Diagnosis and Management of Alzheimer’s Disease, 1999.
Time
De
teri
ora
tion
Motricity(Motor
Function)
Natural History of AD
Time (years)Time (years)
SymptomsSymptoms
DiagnosisDiagnosis
Loss of functional Loss of functional independenceindependence
Behavioural problemsBehavioural problems
Nursing home placemenNursing home placemen
ttDeathDeath
Min
i-M
enta
l Sta
te E
xam
inat
ion
(M
MS
E)
Min
i-M
enta
l Sta
te E
xam
inat
ion
(M
MS
E) Early diagnosisEarly diagnosis Mild-to-moderateMild-to-moderate SevereSevere
11 22 33 44 55 66 77 8899
00
55
1010
1515
2020
2525
3030
Reproduced with permission from Feldman and Gracon, 1996.Reproduced with permission from Feldman and Gracon, 1996.
Alzheimer’s Disease Progresses Through Distinct
Stages
MildMild Moderate Moderate Severe Severe
• Memory lossMemory loss
• Language Language problemsproblems
• Mood swingsMood swings
• Personality Personality changeschanges
• Diminished Diminished judgmentjudgment
•Behavioural, personality Behavioural, personality changeschanges
•Unable to learn/recall new Unable to learn/recall new informationinformation
•Long-term memory affectedLong-term memory affected
•Wandering, agitation, Wandering, agitation, aggression, confusionaggression, confusion
•Require assistance w/ADLRequire assistance w/ADL
•Gait, incontinence, Gait, incontinence, motor disturbancesmotor disturbances
•BedriddenBedridden
•Unable to perform ADLUnable to perform ADL
•Placement in LTC neededPlacement in LTC needed
Average duration 7-10 yearsAverage duration 7-10 years
StageStage
SymptomsSymptoms
Alzheimer’s disease anatomical correlates: 3 phases of illness
• Limbic system: memory
• Parietal: spatial organization, function
• Frontal: behaviour
Cholinergic Pathways From theBasal Forebrain
PC
OCFC B
F H
Frontotemporal Dementia
Frontotemporal dementia
3 clusters of features:
(a) Behavioural (disinhibition, apathy, poor insight and judgement)
(b) Language (progressive expressive type aphasia, contraction of language)
(c) Self neglect
First described by Arnold Pick
Frontotemporal dementia
• Familial in 50%
• Serotoninergic (vs. cholinergic) deficit
• Memory not a prominent feature until late
• Often difficult to manage
Lewy (or Lewey) body dementia
Also known as:
• Dementia with Lewy bodies
• Lewy body dementia
Lewy body dementia
Core features (2 probable, 1 possible):• Fluctuating cognition• Recurrent well formed detailed visual
hallucinations• Spontaneous ParkinsonismSuggestive features (1 possible, 1 plus above,
probable:• REM sleep disorder• Severe neuroleptic sensitivity
McKeith I, et al Neurology 2005; 65: 1863
Lewy body dementia
Supportive features:
• Repeated falls
• Systematized delusions
• Dementia occurs before or concurrently with Parkinsonism
• Early visuospatial dysfunction
• May progress more rapidly than AD
Lewy body dementia
• Severe cholinergic deficit
• Anti Parkinsonian medications may worsen psychosis
• Antipsychotic agents may worsen Parkinsonism
• Cholinesterase inhibitors often work well
Vascular dementia• Dementia follows in wake of stroke
• Presentation will depend upon location and size of stroke
• Clear history of stroke not always present
• Large overlap with Alzheimer’s disease (i.e. mixed dementia)
Multiple large vessel infarcts
Bilateral strategic thalamic infarcts
Binswanger’s disease
Brain Imaging of Vascular dementia
3 Types of VaD
Source: Stephen Salloway, MD
Assessment of Dementia: domains
• Cognitive
• Functional
• Behavioural
• Affective
80 year old lady
• Brought to you by only daughter
• Forgot daughter’s birthday this year
• Missed payment of several bills
• Housework and personal hygiene slipping slightly
80 year old lady: history
80 year old lady: history
• Onset and duration• Focal neurological symptoms• Precipitating events• Past history and risk factors• Social history and risks (fire, wandering,
summoning help, low TI medications)• Medications (all of them)• Order lab tests?
80 year old lady: examination
80 year old lady: examination
• Overall appearance (e.g. cleanliness, grooming, trauma, clothing)
• General physical ( e.g. HF, hypoxia, thyroid, tumours)
• Focal neurological signs
• Gait, balance
80 year old lady: mental status
80 year old lady: mental status
• MMSE or equivalent
• Clock drawing
• Montreal Cognitive Assessment (MoCA)
• Measures of insight & judgement
80 year old lady: laboratory
80 year old lady: laboratory
• CBC
• Blood sugar
• Electrolytes
• TSH
• B12
• Calcium
80 year old lady: neuroimaging
80 year old lady: neuroimaging
• Age under 65• Focal neurological symptoms• Focal neurological signs• Short history• Head trauma• Anticoagulants or bleeding• Malignancy that might metastasize• Atypical features i.e. not suggesting AD
80 year old lady: management
80 year old lady: management
• Disclosure• POA, advance directives• Risk assessment (consider OT)• Transport• Education and support• Alzheimer’s Society or other support
organization• Case manager• Education sessions• Medications
68.8
100.5
113.4120.0
0
20
40
60
80
100
120
140
Mild Mild-to-moderate Moderate Severe
Ho
urs
pe
r m
on
th s
pe
nt
ca
rin
g f
or
AD
pa
tie
nts
AD Caregiver Time by Disease Severity
Hux et al. CMAJ, 1998.
A Family Intervention for people with AD
97 dyads (care giver plus patient ) NYC
Intervention: 2 individual and 4 family counselling
sessions (education & resource information)
After 4 months caregivers meet weekly in support groups
Continuously available counsellors
A Family Intervention for people with AD
Control group received “usual care” Follow up to 8 yearsResults: Median time to nursing home placement
increased by 329 days p=0.02 RR of NH admission 0.65 (0.45,0.94) Effects most marked on those with mild and
moderate dementia
Mittelman S et al JAMA 1996
“Behavioural” Interventions
• Establish routine
• Day programs e.g activities, exercise, socializing
• In home respite
• Distraction, coaching
• Behavioural observation
80 year old lady: management
• Disclosure• POA, advance directives• Risk assessment (consider OT)• Transport• Education and support• Alzheimer’s Society or other support
organization• Case manager• Education sessions• Medications
Cholinesterase Inhibitors
• Have become standard of treatment for mild to moderate Alzheimers Disease ( but also show efficacy in vascular and Lewy body dementia)
• 25-33% of people treated show a noticeable improvement
• Questionable disease stabilization
• Probably all equally efficacious
Clinicalimprovement
Clinicaldecline
No change
0 Week 24 LOCF
(72)(73)
4
n=69n=70
12
6862
18
6464
8
6161
24
6263
DonepezilPlacebo
p=0.0004p=0.0017 p=0.0007
p=0.0006
p=0.002p=0.0002
= 0.7
CIBIC-plusCIBIC-plus
Donepezil in Advanced AD(sMMSE 5-12):Global Function
3.4
3.6
3.8
4.0
4.2
4.4
4.6
4.8
5.0
5.2
Study week
LS
mea
n s
core
± S
E
DonepezilPlacebo
Gauthier S et al. Neurology, 2003.
Cholinesterase Inhibitors: do they work?
• Donepezil (Aricept)
• Rivastigmine (Exelon)
• Galantamine (Reminyl)
• All show modest positive effects on:
ADAS-Cog: WMD -2.62; -3.41; -2.77
CIBIC+: RR 1.37; 1.77; 1.28
AHRQ publication No. 04-E018-2 April 2004
PREVENTING DEMENTIA
We can reduce the incidence of strokes by:
• Control of blood pressure
• Control of other vascular risk factors: Smoking,
Cholesterol
• Regular physical exercise (dancing…)
Preventing Dementia: The SYST-EUR Study
• Multicentre RCT in Europe 2470 participants over age 60; SBP 160-319
• Target: reduction of SBP by 20 mm or <150mm by nitrendipine 10-40mg
• Up to 5 years follow up• After 2 years 11 new cases of dementia in
treated; 21 in placebo p=0.06• Rate of dementia 3.8 vs 7.7 cases per 1000
person years p= 0.05
Forette F et al Lancet 1998; 352:1347
What is new in Pharmacological Treatment?
• Memantine for AD
• Vaccination against AD
• Antibiotics for AD
• Lipid lowering agents for AD
• A word of caution about novel neuroleptics
Memantine
• NMDA antagonist modulates glutamate excitotoxicity
• 28 week RCT involving 252 people with moderate to severe AD (MMSE 3-14)
• Significant improvements on CIBIC plus .5/5; Severe ADL 3/7 & SIB in treated group cf placebo
• Well tolerated• Approved in USA, likely in Canada within next
year
Reisberg et al New Engl J Med 2003;348:1333
Vaccination
• Anti Abeta immunotherapy reduces amyloid deposition and improved spatial cognition in mice
• Clinical trial in 298 patients with AD:18 developed inflammatory meningoencephalitis: study halted
• Autopsy in one: “less amyloid than expected”
Orgogozo J-M et al Neurology 2003;61:46 Mathews P & Nixon R Neurology 2003;61:7
Vaccination
• In subgroup of 30 patients, those who generated Abeta antibodies had reduced disease progression
• Attempts being made to reformulate vaccine
• Passive immunization considered
Hock C et al.Neuron 2003;38:547 Wolfe MS. Nat RevDrug Discov 2002;1:859
Antibiotics for AD
• Higher than normal titres of Chlamydia in people with AD
• Multicentre Canadian double blind placebo controlled RCT
• 101 patients with mild to moderate AD (MMSE 11-25)
• Daily doxycycline 200mg plus rifampin 300mg or placebo for 3 months
Antibiotics for AD
• Standardized ADAS Cog @ 6 months difference of 2.75/70 between treated and placebo group (significant @ 6 but not 12 months)
• Standardized MMSE score 2.2/30 higher @12 (but not 3 or 6) months
• Intriguing results!• Larger study in planning stages
Loeb M, Molloy DW et al JAGS 2004;52:381
Lipid lowering and AD
• Previous observations suggested lower risk of AD in those taking “statins”
• Recently presented at 8th International Symposium on Advances in AD therapy
• Atorvostatin treatment associated with less decline in memory, function, mood & behaviour in people with AD
• Premature to decide until full details available in peer reviewed publication
SUMMARY
• Dementia relatively uncommon in India at present, but prevalence will rise sharply with aging of population
• Best strategies for prevention is control of vascular risk factors, especially hypertension
• Social supports more valuable than medications
• No cure yet!